NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Friday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 1.8 %

NYSE:NBY opened at $0.64 on Friday. The stock has a fifty day simple moving average of $0.64 and a 200 day simple moving average of $0.61. The firm has a market capitalization of $3.15 million, a price-to-earnings ratio of -0.01 and a beta of 0.67. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.